Orthopedics Medical News about muramyl tripeptide, metastatic osteosarcoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
Cancer, 08/03/09

Chou AJ et al. - In a study to examine the addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy for pts with metastatic osteosarcoma (OS), it was found that when the metastatic cohort was considered in isolation, addition of liposomal MTP-PE to chemotherapy did not achieve a statistically significant improvement in outcome. But the pattern of outcome is similar to the pattern in nonmetastatic pts.

Methods

Intergroup-0133 was a prospective randomized phase 3 trial for the treatment of newly diagnosed pts with OS.
3-drug chemotherapy with cisplatin, doxorubicin, and high-dose methotrexate (Regimen A) was compared with the same 3 drugs with the addition of ifosfamide (Regimen B).
Addition of liposomal MTP-PE to chemotherapy was evaluated.

Results

5-yr event-free survival (EFS) for pts who received liposomal MTP-PE (n=46) was 42% vs 26% for those who did not (n=45).
5-yr overall survival for pts who received MTP-PE vs no MTP-PE was 53% and 40%, respectively.
The comparison of Regimen A with Regimen B did not suggest a difference for EFS (35% vs 34%, respectively) or overall survival (52% vs 43%, respectively).

<< Previous
Long-term results of the threaded Weill cup in primary total hip...

Next >>
Metabolic Bone Disease of Prematurity